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In Brief
Perforin-positive dendritic cells (perfDCs) represent a minor subpopulation of myeloid DCs. Based on selective ablation of perf-DCs in radiation chimera, Reisner and colleagues demonstrate that these cells control inflammatory T cells in steady state and play a regulatory role in metabolic syndrome and in experimental autoimmune encephalomyelitis.
INTRODUCTION
Studies of cellular mechanisms involved in maintenance of peripheral immune tolerance have largely focused on T regulatory (Treg) cells, but other key cellular mediators such as B regulatory (B reg) cells, myeloid suppressor cells (MDSCs), and various types of dendritic cells (DCs) have been implicated, as well. DCs have a tolerogenic capacity in their immature state (Dhodapkar et al., 2001; Fu et al., 1996; Jonuleit et al., 2000; Lutz et al., 2000; Tiao et al., 2005; Trinité et al., 2005) . However, this rather simplistic dichotomy between mature and immature DCs has been challenged by the demonstration that fully mature DCs can also induce tolerance under appropriate conditions (Lu et al., 1997; Sü ss and Shortman, 1996; Waithman et al., 2007; Yu et al., 2009 ).
We have recently described the generation of a highly defined population of DCs from Lin
À

Sca1
+ cKit + (LSK) hematopoietic progenitors (Zangi et al., 2012) . These DCs express perforin and granzyme A in discrete granules and are therefore termed ''perf-DCs'' (Zangi et al., 2012) . Perf-DCs are able to selectively kill cognate T cell receptor (TCR) transgenic CD8 + T cells that recognize their peptide-MHC, through a unique perforin and granzyme A-based killing mechanism, regulated through tolllike receptor-7 (TLR7) and triggering receptor expressed on myeloid cells-1 (TREM-1) signaling (Zangi et al., 2012) . We demonstrated by immune histological staining that perf-DCs comprise about 2%-4% of the CD11c-positive cells within the lymph nodes and spleen and that the abundance of these cells is markedly enhanced upon in vivo administration of granulocyte macrophage colony stimulating factor (GM-CSF) (Zangi et al., 2012) . Perforin-positive myeloid DCs have also been reported within the human classical DC population (Stary et al., 2007) . These initial findings, based exclusively on ex vivo studies, indicated a potential tolerogenic role for perf-DCs; however, the relevance of this cell population to tolerance maintenance in the steady state in vivo remained unresolved.
To address this question, we used bone marrow transplantation to generate chimeric mice, in which perforin expression is selectively impaired in CD11c-positive DCs. We found that, within 5 months, these mice developed many features of metabolic syndrome, suggesting that perf-DCs represent an important regulatory population that might control inflammatory processes in the adipose tissue (AT). Our results are in line with the emerging intriguing cross-talk between the immune system and the endocrine AT (Hotamisligil et al., 1993; Weisberg et al., 2003; Xu et al., 2003) . Specifically, these studies suggest that AT dysfunction and metabolic imbalances in obesity are associated with low-grade systemic inflammation.
The antigens that drive AT-specific T cell selection and expansion resulting in the observed AT inflammation are not yet known. We therefore investigated the regulatory role of perf-DCs in a more defined model of autoimmunity, namely experimental autoimmune encephalomyelitis (EAE). In line with our hypothesis that perf-DCs have immuno-regulatory activity, mice lacking these cells were substantially more prone to induction of EAE, exhibiting significantly elevated autoimmune T cell clones compared to their WT counterparts. Collectively, we demonstrate that perf-DCs mediate a key role in steadystate protection from development of metabolic syndrome, as well as in the control of EAE.
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RESULTS
Characterization of Perf-DCs in Radiation Chimeras
As previously described (Zangi et al., 2012) , perf-DCs represent a minor subpopulation ($4%) within the CD11c + population in the spleen of WT C57BL/6 mice ( Figure S1A ). This rare subpopulation of perf-DCs is markedly enhanced upon in vivo administration of GM-CSF (Zangi et al., 2012) , and to a lesser extent, upon treatment with Flt3L (data not shown). Furthermore, as shown in Figure S1B , perforin is expressed in CD11c These percentages indicate the frequencies of each subpopulation out of the entire lymphogate in the organ (spleen or BM). See also Table S1 and Figure S1 .
to intermediate CD11c, are spared in these mice (Birnberg et al., 2008) . To induce a restricted perforin deficiency within the CD11c hi DC population, we generated bone marrow (BM) chimeras using a 1:1 mixture of Prf1 À/À BM (Kä gi et al., 1994) and BM of mice expressing diphtheria toxin alpha chain (DTA) in CD11c hi cells (Itgax-DTA mice) (Birnberg et al., 2008) . Based on the reported properties of the Itgax-DTA mice (Birnberg et al., 2008) , cells other than CD11c hi DCs will be derived in the resulting chimeras (Itgax-DTA-Prf1 À/À ), from both types of donor BM (and hence 50% will express perforin). In contrast, due to the DTA-mediated ablation of perforin-proficient cells, the CD11c hi population will be exclusively derived from the Prf1 À/À donor and therefore lack perforin.
These chimeras should thereby allow us to determine whether the absence of perf-DCs leads to a particular autoimmune phenotype, similarly to that found in mice lacking other immune regulatory cells (Sakaguchi, 2000) . In parallel, we generated control BM chimeras by transplantation of a 1:1 mixture of BM from Prf1 À/À mice and BM from Itgax-DTA-negative littermates (WT-Prf1 À/À mice). Histological evaluation via ImageJ software of cDCs isolated from spleens of Itgax-DTA-Prf1
chimeras confirmed absence of perforin-expressing DCs (0.09% ± 0.19%), whereas in WT-Prf1 À/À chimera the expression of perf-DCs was reduced to 2.4% ± 1.9% from 4.1% ± 1% found in WT mice (data not shown). Confirming our ablation strategy, CD11c hi MHC-II hi cDCs (Figure 1A) , although reaching the same steady-state expression as in the WT-Prf1
À/À chimera ( Figure 1B ), were exclusively derived from the CD45.2 + Prf1 À/À donor ( Figure 1C ). Likewise, BM pre-DCs largely originated from the CD45.2 + Prf1
À/À donor ( Figure 1D ). In contrast, WT-Prf1 À/À chimeras exhibited CD11c hi cells that were equally derived from both BM donors ( Figure 1D ). Notably, T cells, B cells, neutrophils, pDCs, NK cells, and macrophages in the spleen of Itgax-DTA-Prf1 À/À chimeras were equally derived from both BM donors ( Figure 1E , Table  S1 ). These results establish that Itgax-DTA-Prf1 À/À chimeras, in which all CD11c hi DCs are derived from Prf1 À/À donors, and thus do not express perforin, offer a robust model for studying the role of perf-DCs in the steady state.
Perf-DC-Deficient Chimeras Develop Metabolic Syndrome
After the generation of Itgax-DTA-Prf1 À/À chimeras, these mice were followed for a prolonged period to assess the development of a potential pathological phenotype that might be associated with the lack of perf-DCs. Itgax-DTA-Prf1 À/À chimeric mice spontaneously gained significantly more weight compared to Figure 2C ). In addition, the percent of total body fat, as measured by body composition MRI, was significantly elevated in Itgax-DTA-Prf1
À/À mice compared to both control groups (Figure 2 ). Itgax-DTA-Prf1 À/À mice, but not the control chimeras, displayed highly elevated TNF-a (linked to obesity-associated inflammation and insulin resistance) (Hotamisligil et al., 1993) and leptin, the proinflammatory adipokine associated with obesity, overeating, hypertension, cardiovascular diseases, and metabolic syndrome (Figures 2D-2F ; Ouchi et al., 2011 (ECM), and minimal inflammation occur. In contrast, pathological expansion of AT is characterized by rapid growth of the fat pad through enlargement of existing fat cells, pronounced macrophage infiltration, limited vessel development, and massive fibrosis. Such pathological expansion is associated with chronic inflammation, ultimately resulting in the development of systemic insulin resistance (Sun et al., 2011 (IV) cells in the AT-similar to the ones described above for the spleen. Although these subpopulations residing in the AT might differ in function and origin from the splenic cells bearing the same phenotypes, no significant difference in the frequencies of the CD11c hi DCs was found between the two types of chimera ( Figure 
CD8
+ T cells) and serum markers (leptin, TNF-a, IL-1b) starting at 5 months after transplant, we administered weekly i.p. injections of anti-CD4 antibodies, anti-CD8 antibodies, or both, starting 1 month prior to development of the earliest inflammatory signs (4 th month after BM transplant). This treatment resulted in more than 95% depletion of the target population(s) in the spleen, LNs, and peripheral blood, with no changes in other cell populations (data not shown). More importantly, though, we found that Itgax-DTA-Prf1 À/À mice treated with anti-CD4 antibodies, anti-CD8
antibodies, or a combination of them did not gain weight, similar to the WT-Prf1 À/À controls ( Figure 4E ). Likewise, serum leptin was found to be elevated only in the group of Itgax-DTA-Prf1
mice not treated with antibody ( Figure 4F ). This observed role of both CD4 + and CD8 + T cells is consistent with potential triggering of the AT pathology by effector CD8 + T cells requiring initial help from CD4 + T cells.
Because alterations in central regulatory functions are probably involved in the metabolic changes observed, and recent data demonstrate changes in inflammatory status in the hypothalamus that might be important in body weight regulation, we evaluated the expression of interleukin-6 (IL-6) and IL-1b in the hypothalamus of Itgax-DTA-Prf1 À/À and control WT-Prf1
À/À chimeric mice before (4 months after transplant) and after (9 months after transplant) disease onset. We found that these cytokines were indeed elevated in Itgax-DTA-Prf1 À/À chimera, albeit only after disease onset. Thus, although there was no significant difference at 4 months, by 9 months after transplantation IL-6 was four times higher in Itgax-DTA-Prf1 À/À mice compared to WT-Prf1 À/À mice (p < 0.01), and IL-1b was six times higher in Itgax-DTA-Prf1 À/À mice compared to WT-Prf1 À/À mice (p < 0.05), indicating that these changes might be induced as a result of the inflammatory process in AT.
The T Cell Repertoire Is Modified within the Adipose Tissue of Itgax-DTA-Prf1 -/-Chimeras
It is possible that autoimmune T cells are poorly controlled in the absence of regulatory perf-DCs. To address this possibility, the TCR repertoire from AT tissue of Itgax-DTA-Prf1 À/À and WTPrf1 À/À chimeras at 6 months after transplant was analyzed by high-throughput TCR sequencing (Ndifon et al., 2012) . We sequenced the TCRb CDR3 region of T cells and compared the repertoire found in spleen, visceral AT (VAT), and subcutaneous AT (SC-AT) of Itgax-DTA-Prf1 À/À and WT-Prf1 À/À chimeras.
As a measure of the composition of the TCR repertoire, we evaluated the degree of skewing in the frequencies of observed TCR sequences. A more diverse repertoire consists of se- quences that are found at similar frequencies, whereas in a skewed repertoire, a small number of sequences are dominant and are found at higher frequencies. The skewing of a repertoire can be evaluated by the increased deviation of its Lorentz curve from the diagonal. We first compared the repertoires of T cells resident within AT to the repertoire found in the spleen of WT-Prf1 À/À animals. Consistent with previous observations of a restricted TCR repertoire within AT (Feuerer et al., 2009; Winer et al., 2009; Yang et al., 2010) , we observed greater skewing in the repertoires of T cells derived from VAT and SC-AT compared with splenic T cells of WT-Prf1 À/À mice ( Figure 5A ). We also identified specific Vb segments that were enriched in the repertoires derived from AT compared with the splenic repertoire. Next, we compared the TCR repertoires between WT-Prf1 À/À and Itgax-DTA-Prf1
chimeras. Although there was no difference in the spleens of these chimeras, the TCR repertoire observed in the AT tissues derived from Itgax-DTA-Prf1 À/À mice was less skewed than that of the WT-Prf1 À/À mice ( Figure 5A ). Thus, the TCR repertoire in AT of the WT-Prf1 À/À chimera is dominated by expansion of a small number of clonotypes, whereas the Itgax-DTA-Prf1 À/À AT repertoire contains a greater number of distinct T cell clones with intermediate expression. To identify signature TCR sequences that distinguish the two types of chimera, we used an ordination method, similar to principal-component analysis (Yeung and Ruzzo, 2001) , termed redundancy analysis (RDA) (Sady s et al., 2015) . This method attempts to explain the variance in the data, constrained by the grouping of samples, by fitting a linear model that maximizes the variance between groups. With RDA, we selected TCR sequences with the highest contribution to the separation between the experimental groups, resulting in a list of signature sequences that were highly expressed in one group but not in the other. This analysis separated repertoires of Itgax-DTA-Prf1 À/À versus WT-Prf1 À/À mice along the first RDA axis (RDA1), and between most spleen samples versus VAT samples along RDA2 ( Figure 5B ). Next, we identified CDR3 sequences that were most highly enriched in repertoires of Itgax-DTA-Prf1
mice compared with WT-Prf1 À/À , by RDA analysis. Figure 5C shows 16 CDR3b amino acid sequences with the lowest (negative) weights on RDA1, which were enriched in Itgax-DTA-Prf1 À/À mice compared with WT-Prf1 À/À mice. Several TCRb sequences were consistently upregulated across Itgax-DTA-Prf1 À/À animals, suggesting their potential role in the observed phenotype. Of note, many of these TCRs are encoded by different nucleotide sequences in different animals ( Figure S4 ), an indication of clonal selection driven by TCR specificity. These TCR sequences, which exist in the Itgax-DTA-Prf1 À/À but not in the WT-Prf1 À/À animals, might be mechanistically related to the metabolic phenotype, though further studies are required to identify the specificity of the TCRs that distinguish the two types of chimeras.
Itgax-DTA-Prf1 -/-Chimeras Develop Enhanced Obesity in Response to a High-Fat Diet To learn how mice lacking perf-DCs respond to excess adiposity, we used a classical model of obesity, in which mice are chroni- cally fed a high-fat diet (HFD). When fed HFD, normal WT C57BL/6 mice develop glucose intolerance and insulin resistance by the 12 th week, with elevated pro-inflammatory cytokines and adipokines. Itgax-DTA-Prf1 À/À mice have a tendency to spontaneously develop these symptoms, so we followed the dynamics of metabolic and functional changes at early time points. As can be seen in Figures 6A and 6B , Itgax-DTA-Prf1 À/À mice gained weight much earlier than WT-Prf1 À/À chimeras when fed HFD, with higher percentage of body fat, increased liver weight, and epididymal fat pad weight ( Figures 6C-6E ). Furthermore, serum leptin was significantly higher as early as 1 month after initiation of HFD. At 1.5 months from initiation of feeding, insulin and both IL-1b and tumor necrosis factor-a (TNF-a) were elevated in Itgax-DTA-Prf1 À/À mice ( Figures 6F-6H and 6L). Plasma cholesterol and triglycerides were elevated in Itgax-DTA-Prf1 À/À mice relative to control WT-Prf1 À/À animals, starting at 1 month from initiation of HFD ( Figure 6F ), and liver TGs were also markedly higher ( Figures 6I-6K) . Thus, the increased susceptibility to diet-induced obesity could offer an additional, more rapid model for investigating the impact of perf-DCs on different immune cell subpopulations. As in the normal-fat diet, we also found that larger numbers of both CD8 + and CD4 + T cells infiltrated the VAT in Itgax-DTAPrf1 À/À mice fed with HFD compared to controls ( Figure S5 ).
Although there was no significant elevation of macrophages within the VAT of the Itgax-DTA-Prf1 À/À chimera ( Figure S5 ), we found by RT-PCR a significant shift toward a gene expression profile typical of inflammatory M1 macrophages ( Figure 6J ), which is consistent with increased inflammatory properties of macrophages in the AT of obese mice (Lumeng et al., 2007a; Weisberg et al., 2003) . It is possible that activation of T and NK cells upon onset of inflammation or initiation of HFD might induce upregulation of CD11c, and thereby of DT to a degree sufficient to cause the deletion of these populations. Clearly, such deletion would not be apparent in analysis of cell populations in the naive mice, shown in Figure 1 prior to onset of disease. We therefore re-evaluated potential changes in the level of Prf1 À/À -derived cells within various leukocyte populations in the BM, spleen, and VAT before (2 months after BMT) and after (7 months after BMT) the onset of the metabolic phenotype. Likewise, we analyzed such potential changes in chimeric mice after 8 weeks of HFD, by which time the full-blown syndrome develops in Itgax-DTA-Prf1 À/À mice. As shown in Figures S6 and S7 and Table S1 , 
Perf-DCs Exhibit a Major Regulatory Role in EAE
We showed that selective deletion of perforin in the rare subpopulation of perf-DCs leads to a distinct metabolic phenotype and that this phenotype can be prevented by T cell depletion in vivo. This strongly indicates a role for perf-DCs in the control of T-cell-mediated inflammatory processes. However, although we found a skewed TCR repertoire exhibited by AT T cells in Itgax-DTA-Prf1 À/À chimeras, the identity of antigens eliciting this inflammatory response are not known. To further investigate the regulatory role of perf-DCs, we evaluated whether perf-DCs might also exhibit a regulatory role in a well-defined mouse model for autoimmunity, in which the pathological antigen is known. We therefore examined whether Itgax-DTA-Prf1 À/À chimeras are more susceptible to development of EAE, a T-cell-mediated disorder widely used as a model of multiple sclerosis . In this mouse model, MOGinduced EAE results in a chronic persistent disease course. Figure 7D ). MOG-specific IFN-gand IL-17A-positive T cells were also found in the central nervous system (CNS) 14 days after immunization ( Figure 7E ). These results demonstrate the immune-regulatory role of perf-DCs and the ability of these cells to inhibit detrimental expansion of antigen-specific autoimmune clones in the context of EAE.
MOG administration in
DISCUSSION
We have shown here that DCs expressing perforin represent a subpopulation of regulatory DCs with a steady-state role in prevention of inflammatory processes within the AT and in the CNS. The intriguing relationship between metabolism and the immune system has received increasing attention over the past few years (Schipper et al., 2012) . AT is now recognized as a true endocrine organ that plays a fundamental role in controlling whole-body glucose and lipid homeostasis (Guilherme et al., 2008) . Previous studies have identified various immune cells as metabolic controllers with pathogenic or regulatory potential ElgazarCarmon et al., 2008; Feuerer et al., 2009; Kang et al., 2008; Liu et al., 2009; Lumeng et al., 2007a Lumeng et al., , 2007b Nguyen et al., 2007; Nishimura et al., 2013; Odegaard et al., 2007; Osborn and Olefsky, 2012; Talukdar et al., 2012; Wu et al., 2011) . Three T lymphocyte subsets might play distinct roles in AT immune homeostasis: CD8 + T cells (Nishimura et al., 2009 ), IFNg + CD4 + T (Th1) cells (Rocha et al., 2008; Winer et al., 2009) , and Foxp3 + regulatory T (Treg) cells (Eller et al., 2011; Feuerer et al., 2009; Ilan et al., 2010) . In particular, the infiltration of CD8 + T cells to the AT has been shown to precede macrophage influx and M1 polarization in the obese AT (Nishimura et al., 2009; Rausch et al., 2008) , and CD8 + T cells are involved in macrophage recruitment and polarization in obesity (Nishimura et al., 2009 ). Furthermore, as also shown here, depletion of CD8 + T cells in obese mice improved insulin sensitivity, whereas adoptive transfer of CD8 + T cells induces insulin resistance in CD8-deficient mice (Nishimura et al., 2009) .
A major drawback of most of these studies is the reliance on HFD, which does not accurately represent normal steady-state conditions in the AT. Our study showed the major impact of a unique DC subpopulation on AT inflammatory processes in the context of normal dietary conditions. The HFD regimen is associated with further acceleration of disease onset in Itgax-DTAPrf1 À/À chimeras that lack perf-DCs and are susceptible to AT inflammation. Our observations of differences in TCRb repertoires of WT-Prf1 À/À versus Itgax-DTA-Prf1 À/À mice in both adipose tissues tested (VAT and SC-AT), but not in the spleen, suggest that specific T cells are missing from the adipose tissue of WT-Prf1 À/À animals, potentially due to their deletion by regulatory perf-DCs. The possibility that the phenotype might be mediated by antigen-specific T cells that escape regulation in the absence of perf-DCs is supported by the observation that the inflammatory AT phenotype can be completely prevented by T cell depletion using either anti-CD4 or anti-CD8 antibodies.
As expected from previous studies in mice fed HFD (De Souza et al., 2005) , this inflammatory process is also accompanied by late increase in IL-6 and IL-1B expression in the hypothalamus. However, the late onset of this process in Itgax-DTA-Prf1
À/À chimeras indicates that it might be induced by the phenotype rather than cause it.
In our chimeric mouse model, the T cell compartment must reconstitute itself after transfer of BM to irradiated recipients. Such reconstitution is slow, requiring about 2 months in mice. Thus, we expect a delay in the replenishment of fat-resident T cells at least of that magnitude, and possibly even longer, due to slower traffic of T cells into the fat tissue. Only when sufficient numbers of self-reactive T cells accumulate in the fat tissue are inflammatory processes initiated.
Considering that DTA mice tend to develop a myeloproliferative disorder at old age, it could be argued that such a pathological process might be somehow associated with the phenotype observed in our Itgax-DTA-Prf1 À/À chimera, which also develops late after transplantation. However, we did not detect in our chimeric mice any sign of myeloproliferative disorder, in line with Birnberg et al. (2008) , who showed in their original paper that this phenotype did not develop in BM chimera established by combining BM from DTA mice with BM from WT mice. The Itgax promoter is also active in cells other than DCs, including some NK cells, macrophages, and pDCs, although the specific Itgax promoter fragment used for the Itgax-cre transgenic mice is inactive in certain cells (CD11c int moDCs, CD11c int PDCs, and NK cells) that transcribe their endogenous Itgax alleles (Bar-On and Jung, 2010). Nevertheless, we extensively evaluated the possibility that our observed phenotype might be associated with ablation of these cells in our Itgax-DTA-Prf1 À/À chimera. Thus we studied in our Itgax-DTA-Prf1 À/À and WT-Prf1 À/À chimeras the expression of markers associated with NK cells (NK1.1, NKp46, and CD49b(DX5)), macrophages (F4/80), and pDCs (PDCA-1), and we confirmed the previous suggestion of Bar-On and Jung (2010) that these cells, which express intermediate or low CD11c, are not ablated by DTA. Thus, they are equally derived in the Itgax-DTA-Prf1 À/À chimera from both BM donors.
These results are in line with our previous work on perf-DCs generated in vitro from hematoipoietic stem cells (HSCs), negating the possibility of overlap between these cells and the so-called natural killer dendritic cells (NKDCs) or interferonproducing killer dendritic cells (IKDCs), previously reported to exhibit dual NK and DC properties (Chan et al., 2006; Pillarisetty et al., 2005; Taieb et al., 2006) or activated NK cells (Blasius et al., 2007; Vosshenrich et al., 2007) , as we demonstrated that perfDCs do not express markers typically associated with NK cells, such as NK1.1, DX5, and NKp46, and are negative for B220, which is expressed by IKDCs.
It could be argued that if indeed ablation of perf-DCs is critical for our observed phenotype, one would expect that Prf1 À/À mice, in which the mutation is expressed in every cell, would be similarly susceptible to obesity. However, in such mice both parts of the equation are impacted. Thus, not only perf-DCs, but also perforin-positive effector T cells or NK cells critical for inflammation, are missing, and therefore it is hard to predict the overall outcome. In fact, in parallel to the submission of our manuscript, a new study was published suggesting that Prf1 À/À mice exhibit enhanced obesity and some metabolic disturbances (Revelo et al., 2015) . However, we observed only minor weight gain with no increase in cholesterol or TG, and no changes in the ability to handle glucose and insulin challenges compared to WT mice (not shown).
Taken together, our results suggest that under physiological conditions, perf-DCs probably induce deletion of specific selfreactive T cells, potentially through presentation of tissue-specific self-antigens. In the case of adipose tissue, this leads to deletion of tissue-resident T cells that have inflammatory capacity, thereby contributing to immune tolerance. Thus, the appearance of metabolic syndrome upon specific ablation of perf-DCs in our experiments appears to be a consequence of reduced deletion of those harmful T cells, resulting in adipose inflammation. Furthermore, our results strongly suggest that in the steady state, a unique population of perf-DCs attenuates the severity of EAE by specifically controlling CD4 + T cells that produce IL-17
and IFN-g upon activation by their cognate antigen. The results shown in the present study collectively demonstrate that perf-DCs exhibit an essential role in regulating the delicate balance between immune cells and the fat tissue, and consequently, the entire cascade leading to metabolic syndrome and its associated type 2 diabetes. Thus, we suggest that future therapies could operate by shifting the homeostatic balance of perf-DC abundance and that of other immune cell populations, and their activation state. This might be attained either by inhibiting their ecological competitors or by giving them a growth or accumulation advantage. Our insights regarding the role of perf-DCs might offer opportunities for new rational therapeutics, directed not only at controlling aberrant T cell clones, but also at addressing the regulatory possibilities offered by perf-DCs.
Perforin deficiency within the myeloid DC population results in enhanced susceptibility to EAE. Therefore, perf-DCs might represent, in addition to Treg cells, a regulatory cell population, critical for protection from autoimmunity and AT inflammatory processes. Further studies of these regulatory cells in normal human subjects and in patients is required to establish the translational value of our findings, which could potentially lead to important therapeutic approaches. . In most cases a dominant nt clonotype is present in all tissues from the same animal. This suggests that following clonal expansion, this clonotype populates both fat and splenic tissues. Moreover, in many cases (e.g. CGARGQNTGQLYF), we observe heterogeneity across Itgax-DTA-Prf1-/-mice in terms of the dominant nt sequence for the same AA clonotype, where in each mouse a different nt sequence is dominant. These findings suggest that those clones, which are enriched in the Itgax-DTA-Prf1-/-and are absent (or found at very low frequencies) in WT-Prf1-/-, were subject to TCR-specific positive selection (VAT = Visceral adipose tissue, SPL = Spleen, SC = Sub-cutaneous fat). Table S1 : T cell analysis of spleen cells from Itgax-DTA-Prf1-/-vs WT-Prf1-/-mice fed NCD or HFD (Ave±SD; N≥5) (referring to figure 1). T cell subsets from spleen of Itgax-DTA-Prf1-/-or WT-Prf1-/-mice fed either NCD for 7 months, or HFD for 8 weeks were defined by various markers including CD3, CD8, CD4, CD44, CD62L, CD25 and Foxp3, and analyzed by FACS. T cell subsets from chimera were also stained for CD45.1 to identify cell origin from Itgax -DTA or littermate control hosts, versus CD45.2 expressed by Prf1-/-donors.
